| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis |
|
Medicine details |
|
| Medicine name | natalizumab (Tysabri®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 215 |
| Indication | Single disease-modifying therapy in highly active relapsing–remitting multiple sclerosis for the following groups: patients with high disease activity despite treatment with beta-interferon and patients with rapidly evolving severe relapsing-remitting multiple sclerosis |
| Company | Biogen Idec Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/10/2006 |
| NICE guidance | |